Similar Items: Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non‐Squamous Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study
- First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307
- Conversion therapy for advanced hepatocellular carcinoma following complete response to transarterial radioembolization combined with atezolizumab and bevacizumab
- Safety and Clinical Outcomes of Kanglaite Injection in Combination with Toripalimab and Chemotherapy for Advanced Non-Small Cell Lung Cancer: A Real-World Retrospective Analysis
- Prospective Multicenter Observational Study of Anlotinib in Advanced Non‐Small Cell Lung Cancer: Real‐World Evidence From China
- Prognostic Value of the Aggregate Inflammation Systemic Index (AISI) in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter Retrospective Study
- The combination of atezolizumab and BCG in high-risk non-muscle invasive bladder cancer: results of the phase Ib/II BladderGATE clinical trial